These findings put forward RSPO2 and RSPO3 as novel, clinically relevant cancer drivers in the intestinal tract, which has accordingly been recognized by a clinical trial targeting RSPO3 in colorectal cancer [14]. Here, RSPO2 is linked to colorectal cancer.